In lung cancer patients, the plasma levels (median[range]) of sHLA-G were significantly increased compared with healthy controls (34 ng/mL [3.6–160] vs. 14 ng/mL [0–98]). The gene discussed is HLA-G; the disease is lung carcinoma.